{"data":[{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLSP, L.P.","reportingCik":"0001879466","personType":"PN","sharesOwned":10424224,"percentOfClass":8.7,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLSP, L.L.C.","reportingCik":"0001879465","personType":"OO","sharesOwned":10424224,"percentOfClass":8.7,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":"0001863769","personType":"PN","sharesOwned":10424224,"percentOfClass":8.7,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"Patrick J. Heron","reportingCik":"0001365617","personType":"IN","sharesOwned":7329857,"percentOfClass":6.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"James N. Topper","reportingCik":"0001341382","personType":"IN","sharesOwned":7329857,"percentOfClass":6.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLS X, L.L.C.","reportingCik":"0001790811","personType":"OO","sharesOwned":7329857,"percentOfClass":6.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLS X, L.P.","reportingCik":"0001790880","personType":"PN","sharesOwned":7329857,"percentOfClass":6.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":"0001790879","personType":"PN","sharesOwned":7329857,"percentOfClass":6.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"Frazier Lifesciences Sponsor LLC","reportingCik":"0001828906","personType":"OO","sharesOwned":3968000,"percentOfClass":3.3,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":"0001911592","personType":"PN","sharesOwned":1319923,"percentOfClass":1.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":"0001911623","personType":"OO","sharesOwned":1319923,"percentOfClass":1.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLS XI, L.P.","reportingCik":"0001911580","personType":"PN","sharesOwned":1319923,"percentOfClass":1.1,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLS XII, L.P.","reportingCik":"0002052246","personType":"PN","sharesOwned":365231,"percentOfClass":0.3,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":"0002052255","personType":"PN","sharesOwned":365231,"percentOfClass":0.3,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-26-001215","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2026-09-18","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":"0002052177","personType":"OO","sharesOwned":365231,"percentOfClass":0.3,"filedAt":"2026-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000315066-26-002082","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY NV","ticker":"NAMS","cusip":"N62509109","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":10339663,"percentOfClass":8.8,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000315066-26-002082","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY NV","ticker":"NAMS","cusip":"N62509109","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":10339663,"percentOfClass":8.8,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001422849-26-000108","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Common Stock","eventDate":"2026-05-29","reportingPerson":"Capital World Investors","reportingCik":null,"personType":"IA","sharesOwned":12188377,"percentOfClass":10.4,"filedAt":"2026-06-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-26-224656","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2026-05-12","reportingPerson":"BCLS Fund III Investments, LP","reportingCik":"0001952107","personType":"PN","sharesOwned":2059896,"percentOfClass":1.76,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-26-224656","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2026-05-12","reportingPerson":"Bain Capital Life Sciences Opportunities III, LP","reportingCik":"0001950105","personType":"PN","sharesOwned":1257141,"percentOfClass":1.06,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-26-224656","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2026-05-12","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":"0001814474","personType":"PN","sharesOwned":375512,"percentOfClass":0.32,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-26-224656","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2026-05-12","reportingPerson":"BCLS II Investco, LP","reportingCik":"0001818893","personType":"PN","sharesOwned":114017,"percentOfClass":0.1,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-26-224656","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2026-05-12","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":"0001773187","personType":"PN","sharesOwned":89142,"percentOfClass":0.08,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-26-224656","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":"N62509109","securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2026-05-12","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":"0001702921","personType":"PN","sharesOwned":10857,"percentOfClass":0.01,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000315066-26-001273","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY NV","ticker":"NAMS","cusip":"N62509109","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":8765811,"percentOfClass":7.6,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000315066-26-001273","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY NV","ticker":"NAMS","cusip":"N62509109","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":8765811,"percentOfClass":7.6,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Shabet Rose Sharon","reportingCik":null,"personType":"IN","sharesOwned":4203567,"percentOfClass":3.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":null,"personType":"PN","sharesOwned":4203567,"percentOfClass":3.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":null,"personType":"OO","sharesOwned":4203567,"percentOfClass":3.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":null,"personType":"IN","sharesOwned":4203567,"percentOfClass":3.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Ott David C.","reportingCik":null,"personType":"IN","sharesOwned":4203567,"percentOfClass":3.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2817205,"percentOfClass":2.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":2817205,"percentOfClass":2.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":null,"personType":"PN","sharesOwned":2817205,"percentOfClass":2.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Drawdown GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1386362,"percentOfClass":1.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Drawdown Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1386362,"percentOfClass":1.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000905148-26-000880","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Co N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Drawdown (Aggregator) LP","reportingCik":null,"personType":"PN","sharesOwned":1386362,"percentOfClass":1.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000315066-26-000486","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY NV","ticker":"NAMS","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":6412984,"percentOfClass":5.7,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0000315066-26-000486","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY NV","ticker":"NAMS","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":6412984,"percentOfClass":5.7,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-308141","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-12-02","reportingPerson":"BCLS Fund III Investments, LP","reportingCik":"0001952107","personType":"PN","sharesOwned":5376356,"percentOfClass":4.7,"filedAt":"2025-12-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-308141","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-12-02","reportingPerson":"Bain Capital Life Sciences Opportunities III, LP","reportingCik":"0001950105","personType":"PN","sharesOwned":1257141,"percentOfClass":1.1,"filedAt":"2025-12-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-308141","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-12-02","reportingPerson":"BCLS II Investco, LP","reportingCik":"0001818893","personType":"PN","sharesOwned":297557,"percentOfClass":0.3,"filedAt":"2025-12-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-308141","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-12-02","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":"0001814474","personType":"PN","sharesOwned":375512,"percentOfClass":0.3,"filedAt":"2025-12-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-308141","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-12-02","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":"0001773187","personType":"PN","sharesOwned":89142,"percentOfClass":0.1,"filedAt":"2025-12-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-308141","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-12-02","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":"0001702921","personType":"PN","sharesOwned":10857,"percentOfClass":0.01,"filedAt":"2025-12-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001422849-25-000077","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Capital World Investors","reportingCik":null,"personType":"IA","sharesOwned":9822711,"percentOfClass":8.7,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-272748","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-11-05","reportingPerson":"Bain Capital Life Sciences Opportunities III, LP","reportingCik":"0001950105","personType":"PN","sharesOwned":11422504,"percentOfClass":9.99,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-272748","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-11-05","reportingPerson":"BCLS Fund III Investments, LP","reportingCik":"0001952107","personType":"PN","sharesOwned":11422504,"percentOfClass":9.99,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-272748","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-11-05","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":"0001773187","personType":"PN","sharesOwned":11422504,"percentOfClass":9.99,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-272748","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-11-05","reportingPerson":"BCLS II Investco, LP","reportingCik":"0001818893","personType":"PN","sharesOwned":11422504,"percentOfClass":9.99,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-272748","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-11-05","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":"0001814474","personType":"PN","sharesOwned":11422504,"percentOfClass":9.99,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-272748","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value Euro 0.12 per share","eventDate":"2025-11-05","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":"0001702921","personType":"PN","sharesOwned":11422504,"percentOfClass":9.99,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLSP, L.P.","reportingCik":"0001879466","personType":"PN","sharesOwned":8623939,"percentOfClass":7.7,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLSP, L.L.C.","reportingCik":"0001879465","personType":"OO","sharesOwned":8623939,"percentOfClass":7.7,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":"0001863769","personType":"PN","sharesOwned":8623939,"percentOfClass":7.7,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLS X, L.P.","reportingCik":"0001790880","personType":"PN","sharesOwned":7329857,"percentOfClass":6.5,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":"0001790879","personType":"PN","sharesOwned":7329857,"percentOfClass":6.5,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLS X, L.L.C.","reportingCik":"0001790811","personType":"OO","sharesOwned":7329857,"percentOfClass":6.5,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"James N. Topper","reportingCik":"0001341382","personType":"IN","sharesOwned":7329857,"percentOfClass":6.5,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"Patrick J. Heron","reportingCik":"0001365617","personType":"IN","sharesOwned":7329857,"percentOfClass":6.5,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"Frazier Lifesciences Sponsor LLC","reportingCik":"0001828906","personType":"OO","sharesOwned":3968000,"percentOfClass":3.5,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":"0001911623","personType":"OO","sharesOwned":1179926,"percentOfClass":1,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLS XI, L.P.","reportingCik":"0001911580","personType":"PN","sharesOwned":1179926,"percentOfClass":1,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":"0001911592","personType":"PN","sharesOwned":1179926,"percentOfClass":1,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":"0002052177","personType":"OO","sharesOwned":68567,"percentOfClass":0.1,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":"0002052255","personType":"PN","sharesOwned":68567,"percentOfClass":0.1,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001231919-25-000416","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001936258","issuerName":"NEWAMSTERDAM PHARMA COMPANY N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, nominal value EUR0.12 per share","eventDate":"2025-11-01","reportingPerson":"FHMLS XII, L.P.","reportingCik":"0002052246","personType":"PN","sharesOwned":68567,"percentOfClass":0.1,"filedAt":"2025-11-04","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-225170","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, Nominal value 0.12 per share","eventDate":"2025-09-26","reportingPerson":"ForGrowth NAP B.V.","reportingCik":null,"personType":"OO","sharesOwned":9316914,"percentOfClass":8.3,"filedAt":"2025-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-225170","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, Nominal value 0.12 per share","eventDate":"2025-09-26","reportingPerson":"Forbion Capital Fund IV Cooperatief U.A.","reportingCik":"0001823747","personType":"OO","sharesOwned":4668889,"percentOfClass":4.1,"filedAt":"2025-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-225170","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, Nominal value 0.12 per share","eventDate":"2025-09-26","reportingPerson":"Forbion IV Management B.V.","reportingCik":null,"personType":"OO","sharesOwned":4668889,"percentOfClass":4.1,"filedAt":"2025-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-225170","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, Nominal value 0.12 per share","eventDate":"2025-09-26","reportingPerson":"Forbion Growth Opportunities Fund I Cooperatief U.A.","reportingCik":null,"personType":"OO","sharesOwned":4648025,"percentOfClass":4.1,"filedAt":"2025-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/nams"},{"accessionNo":"0001193125-25-225170","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001936258","issuerName":"NewAmsterdam Pharma Company N.V.","ticker":"NAMS","cusip":null,"securityClass":"Ordinary Shares, Nominal value 0.12 per share","eventDate":"2025-09-26","reportingPerson":"Forbion Growth Management B.V.","reportingCik":null,"personType":"OO","sharesOwned":4648025,"percentOfClass":4.1,"filedAt":"2025-09-30","canonicalUrl":"https://xoomar.com/markets/stocks/nams"}],"updatedAt":"2026-11-03T13:38:22.117Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/nams","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}